Risk factors for <scp>CAR‐T</scp> cell manufacturing failure among <scp>DLBCL</scp> patients: A nationwide survey in Japan
-
- 城, 友泰
- Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital; Department of Hematology and Oncology, Kyoto University Hospital
-
- 吉原, 哲
- Department of Transfusion Medicine and Cell Therapy, Hyogo Medical University Hospital; Department of Hematology, Hyogo Medical University Hospital
-
- 奥山, 美樹
- Division of Transfusion and Cell Therapy, Tokyo Metropolitan Komagome Hospital
-
- 藤井, 敬子
- Division of Transfusion, Okayama University Hospital
-
- 平安山, 知子
- Center for Cellular and Molecular Medicine, Kyushu University Hospital
-
- 加畑, 馨
- Department of Hematology, Hokkaido University, Faculty of Medicine
-
- 山﨑, 理絵
- Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine
-
- 武田, 航
- Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital
-
- 梅澤, 佳央
- Department of Hematology, Tokyo Medical and Dental University
-
- 福島, 健太郎
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine
-
- 芦田, 隆司
- Division of Hematology and Rheumatology, Department of Internal Medicine, Kindai University Hospital
-
- 藤原, 実名美
- Division of Blood Transfusion and Cell Therapy, Tohoku University Hospital
-
- 葉名尻, 良
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
-
- 米谷, 昇
- Department of Hematology, Kobe City Medical Center General Hospital
-
- 多田, 雄真
- Department of Hematology, Osaka International Cancer Institute
-
- 志村, 勇司
- Department of Blood Transfusion, University Hospital, Kyoto Prefectural University of Medicine
-
- 錦井, 秀和
- Department of Hematology, University of Tsukuba
-
- 柴, 徳生
- Department of Division of Blood Transfusion and Cell Therapy, Yokohama City University
-
- 三村, 尚也
- Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital
-
- 安藤, 純
- Department of Cell Therapy and Transfusion Medicine, Juntendo University School of Medicine
-
- 佐藤, 貴之
- Department of Haematology and Oncology, Kurashiki Central Hospital
-
- 中嶋, 康博
- Department of Hematology, Osaka Metropolitan University Hospital
-
- 池本, 純子
- Department of Hematology, Hyogo Medical University Hospital
-
- 岩木, 啓太
- Division of Blood Transfusion and Cell Therapy, Tohoku University Hospital
-
- 藤原, 慎一郎
- Division of Cell Transplantation and Transfusion, Jichi Medical University Hospital
-
- 李, 政樹
- Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
-
- 長村, 登紀子
- Department of Cell Processing and Transfusion, The Institute of Medical Science, The University of Tokyo
-
- 田野﨑, 隆二
- Department of Hematology, Hokkaido University, Faculty of Medicine
-
- 新井, 康之
- Department of Clinical Laboratory Medicine and Center for Research and Application of Cellular Therapy, Kyoto University Hospital; Department of Hematology and Oncology, Kyoto University Hospital
書誌事項
- タイトル別名
-
- Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
この論文をさがす
説明
For successful chimeric antigen receptor T (CAR-T) cell therapy, CAR-T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR-T cell manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B-cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical factors between 30 cases that failed (7.4%) with those that succeeded (n = 378). Among the failures, the proportion of patients previously treated with bendamustine (43.3% vs. 14.8%; p < 0.001) was significantly higher, and their platelet counts (12.0 vs. 17.0 × 10⁴/μL; p = 0.01) and CD4/CD8 T-cell ratio (0.30 vs. 0.56; p < 0.01) in peripheral blood at apheresis were significantly lower than in the successful group. Multivariate analysis revealed that repeated bendamustine use with short washout periods prior to apheresis (odds ratio [OR], 5.52; p = 0.013 for ≥6 cycles with washout period of 3–24 months; OR, 57.09; p = 0.005 for ≥3 cycles with washout period of <3 months), low platelet counts (OR, 0.495 per 105/μL; p = 0.022) or low CD4/CD8 ratios (<one third) (OR, 3.249; p = 0.011) in peripheral blood at apheresis increased the risk of manufacturing failure. Manufacturing failure remains an obstacle to CAR-T cell therapy for DLBCL patients. Avoiding risk factors, such as repeated bendamustine administration without sufficient washout, and risk-adapted strategies may help to optimize CAR-T cell therapy for DLBCL patients.
収録刊行物
-
- British Journal of Haematology
-
British Journal of Haematology 202 (2), 256-266, 2023-07
British Society for Haematology
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1050015333084131840
-
- ISSN
- 13652141
- 00071048
-
- HANDLE
- 2433/284127
-
- PubMed
- 37096915
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- IRDB
- Crossref
- KAKEN
- OpenAIRE
